NCT07008027
Real World Asparaginase Therapy Toxicity
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date pushed from Nov 2026 to Dec 2026
- Site details revised
- Minor Start date pushed from Oct 2026 to Nov 2026
- Notable Eligibility criteria expanded, about 6 words
- Start date: Sep 2026 to Oct 2026
- Site details revised
- Study description expanded, about 1 word
- Minor Start date: Aug 2026 to Sep 2026v10
- Minor Start date: Jul 2026 to Aug 2026v9
Show 7 earlier versionsHide 7 earlier versions
- Minor Start date: Jun 2026 to Jul 2026v8
- Minor Start date: May 2026 to Jun 2026
- Site contact updated
- Notable Start date: Mar 2026 to May 2026v6
- Minor Start date: Jan 2026 to Mar 2026v5
- Notable Start date: Nov 2025 to Jan 2026v4
- Minor Start date: Oct 2025 to Nov 2025v3
- Notable Start date: Jul 2025 to Oct 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities during standard of care (SOC) therapy
Timeframe: Approximately 2½ to 3 years
Probability of developing CTCAE grade 3+ (3, 4, 5) or 4+ (4, 5) toxicities SJALL23T therapy
Timeframe: Approximately 2½ to 3 years
Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SOC therapy
Timeframe: Approximately 2½ to 3 years
Cumulative incidence (CIN) of the grade 3+ or 4+ toxicities throughout SJALL23T therapy
Timeframe: Approximately 2½ to 3 years
Probabilities of grade 3+ or 4+ toxicities each phase of SOC treatment
Timeframe: Approximately 2½ to 3 years
Probabilities of grade 3+ or 4+ toxicities each phase of SJALL23Ttreatment
Timeframe: Approximately 2½ to 3 years
Arms and interventions
Non-protocol therapy /standard of care therapy
Participants receiving non -protocol standard if care (SOC) treatment.
SJALL23T (NCT06390319) protocol therapy
Participants receiving protocol therapy on SJALL23T and not receiving investigational drug.
Sites
1 site in 1 country
- St. Jude Children's Research HospitalMemphis, Tennessee, United States